



RAVIMIAMET

Clinical Trial Accountable
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4058 Basel
SWITZERLAND

22.02.2024 nr RKU-4/14

DECISION

to grant authorisation for clinical trial on the basis of Regulation (EU) No 536/2014 of the European Parliament and of the council

State Agency of Medicines has received the application from sponsor F. Hoffmann-La Roche AG on 11.01.2024 to conduct a clinical trial under the conditions stipulated in Regulation (EU) No 536/2014 art 5 (1) and § 99¹ (1) of Estonian Medicinal Products Act (MPA).

Based on art 8 of Regulation (EU) No 536/2014, considering the aspects covered by Part I and Part II of the assessment report, on the basis of § 99⁶ section 1 p 1 and (3) of Medicinal Product Act

State Agency of Medicines has decided to give the approval to conduct the clinical study protocol no MO42541 under the following conditions:

protocol no: MO42541 (Version 5, dated March 31, 2023)

full title of the trial: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS SORAFENIB OR LENVATINIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB

sponsor of the trial: F. Hoffmann-La Roche AG

number of subjects in Estonia: 9

principal investigators and study locations:

- Dr Andrus Mägi, Tartu University Hospital, L. Puusepa tn 1a, 50406 Tartu, Estonia
- Dr Anu Planken, North Estonia Medical Centre Foundation, J. Sütiste tee 19, 13419 Tallinn, Estonia

The addressee may file a challenge with State Agency of Medicines within 30 days as of the day when the addressee became or should have become aware of the decision as prescribed in Code of Administrative Procedure § 71(1). If the addressee wishes to have the decision to annulled by the administrative court, he or she may submit a complaint to the Tartu

Administrative Court as prescribed in § 7(1) and § 46(1) of the Code of Administrative Court Procedure within 30 days after the date on which the decision was notified to the applicant.

(digitally signed)

Katrin Kiisk
Director General